Dengue vaccine a step closer?

India’s first phase 3 trial hits 50% enrolment mark, early data shows no safety concerns

- 

India has reached the 50 per cent enrolment mark in its first phase III clinical trial for the indigenous tetravalent dengue vaccine, DengiAll, with over 7,000 participants randomised across 20 trial sites. Initial results show no safety concerns for the one-shot vaccine to fight the mosquito-borne viral disease, according to researchers.Developed by Panacea Biotec Limited under a licensing agreement with the National Institutes of Health (NIH), the primary US federal agency for biomedical research, DengiAll targets all four dengue virus subtypes and has shown promising results in earlier clinical trials.